SEC Company Response from Citius Pharmaceuticals, Inc. (CTXR) (CIK 0001506251) (CTXR) — Sep 20, 2019

Citius Pharmaceuticals, Inc. (CTXR) (CIK 0001506251)
Date: Sept. 20, 2019 · CIK: 0001506251 · Accession: 0001213900-19-018549

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-233759

Date

September 20, 2019

Author

H.C. WAINWRIGHT & CO., LLC

Form

CORRESP

Company

Citius Pharmaceuticals, Inc. (CTXR) (CIK 0001506251)

Letter

Re: Citius Pharmaceuticals, Inc.

September 20, 2019

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Registration Statement on Form S-1 (Registration No. 333-233759)

Concurrence in Acceleration Request

Ladies and Gentlemen:

H.C. Wainwright & Co., LLC (“Wainwright”), as underwriter for the referenced offering, hereby concurs in the request by Citius Pharmaceuticals, Inc. that the effective date of the above-referenced registration statement be accelerated to 5:15 p.m. (Eastern Time), or as soon as practicable thereafter, on September 24, 2019, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is aware of its obligations under the Securities Act in connection with this offering.

Very truly yours,
H.C. WAINWRIGHT & CO., LLC

Show Raw Text

CORRESP
1
filename1.htm

September 20, 2019

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

    Re:
    Citius Pharmaceuticals, Inc.

    Registration Statement on Form S-1 (Registration No. 333-233759)

    Concurrence in Acceleration Request

Ladies and Gentlemen:

H.C. Wainwright & Co.,
LLC (“Wainwright”), as underwriter for the referenced offering, hereby concurs in the request by Citius Pharmaceuticals,
Inc. that the effective date of the above-referenced registration statement be accelerated to 5:15 p.m. (Eastern Time), or as soon
as practicable thereafter, on September 24, 2019, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is
aware of its obligations under the Securities Act in connection with this offering.

    Very truly yours,

    H.C. WAINWRIGHT & CO., LLC

    By:
    /s/ Mark W. Viklund

    Name: Mark W. Viklund

Title: Chief Executive Officer

SecProbe.io